Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) released its quarterly earnings results on Friday. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03), RTT News reports. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. During the same quarter last year, the company posted $0.14 earnings per share. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Trading Up 3.5 %

Amneal Pharmaceuticals stock traded up $0.29 during trading hours on Friday, reaching $8.67. 2,898,126 shares of the stock were exchanged, compared to its average volume of 1,319,121. The company has a market cap of $2.69 billion, a P/E ratio of -12.75 and a beta of 1.10. Amneal Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $9.48. The stock has a 50 day moving average of $8.10 and a two-hundred day moving average of $8.32.

Analyst Upgrades and Downgrades

Several research firms recently commented on AMRX. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $9.00 to $12.00 in a research note on Monday, February 24th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, Piper Sandler upped their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $10.60.

Insiders Place Their Bets

In other news, Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the sale, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 160,000 shares of company stock worth $1,292,000 over the last ninety days. Corporate insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.